AVEO Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AVEO Pharmaceuticals, Inc.
Korea Q1 Roundup: Mixed Earnings Amid M&A, Prescription Sales
Large Korean pharma firms’ first-quarter earnings were mostly mixed on a range of diverse factors such as solid prescription sales and impacts from acquisitions, with some even looking to space for new business opportunities.
How KIMCo Is Orchestrating Korean Pharma Collaborations
KIMCo CEO Kevin Kyunghwa Huh talks about the consortium's efforts to become a platform of collaboration for Korean pharmas, including plans for the latest joint investment project as well as how the domestic industry is evolving in terms of globalization and open innovation.
Will The Dark Tunnel For Korean Biopharmas End In 2023?
Scrip wraps up major R&D and corporate developments for Korean biopharmas in 2022 and outlines what lies ahead for them in the new year.
AVEO Acquisition Brings LG Chem Marketed Oncology Drug, US Commercial Footprint
The acquisition of the US oncology-focused firm will immediately build the commercial presence of the affiliate of the major South Korean conglomerate in oncology through Fotivda, while bringing LG Chem a step closer to its ambitions of becoming a major global pharma operation.
- Drug Discovery Technologies
Drug Discovery Technologies
- Other Names / Subsidiaries
- AVEO Oncology
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.